The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Pandya, Pankita H ^a   Murray, Mary E ^a   Pollok, Karen E ^a   Renbarger, Jamie L ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; MALIGNANT NEOPLASM; NONHUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES;

BIOMARKERS, TUMOR; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PRECISION MEDICINE;

EID: 85009374143     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/4273943     Document Type: Article

References (76)

1. J. L. Adams, J. Smothers, R. Srinivasan, and A. Hoos, "Big opportunities for small molecules in immuno-oncology, " Nature Reviews Drug Discovery, vol. 14, no. 9, pp. 603-621, 2015.
2. K. Murphy, P. Travers, and M. Walport, "Principles of innate and adaptive immunity, " in Janeway's Immunobiology, pp. 1-38, Garland Science Taylor and FrancisGroup, NewYork, NY, USA, 7th edition, 2008.
3. M. D. Vesely, M. H. Kershaw, R. D. Schreiber, and M. J. Smyth, "Natural innate and adaptive immunity to cancer, " Annual Review of Immunology, vol. 29, pp. 235-271, 2011.
4. R. D. Schreiber, L. J. Old, and M. J. Smyth, "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, " Science, vol. 331, no. 6024, pp. 1565-1570, 2011.
5. A. Hoos and C. M. Britten, "The immuno-oncology framework enabling a new era of cancer therapy a new era of cancer therapy, " OncoImmunology, vol. 1, no. 3, pp. 334-339, 2012.
6. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2015, " CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5-29, 2015.
7. S. S. Pinho and C. A. Reis, "Glycosylation in cancer: mechanisms and clinical implications, " Nature Reviews Cancer, vol. 15, no. 9, pp. 540-555, 2015.
8. S. Sharma, T. K. Kelly, and P. A. Jones, "Epigenetics in cancer, " Carcinogenesis, vol. 31, no. 1, pp. 27-36, 2009.
9. H. Akhavan-Niaki and A. A. Samadani, "DNAmethylation and cancer development: molecular mechanism, " Cell Biochemistry and Biophysics, vol. 67, no. 2, pp. 501-513, 2013.
10. M. Ehrlich, "DNAmethylation in cancer: toomuch, but also too little, " Oncogene, vol. 21, no. 35, pp. 5400-5413, 2002.
11. H. Lodish, A. Berk, S. L. Zipursky, P. Matsudaira, D. Baltimore, and J. Darnell, "Tumor cells and the onset of cancer, " in Molecular Cell Biology, W. H. Freeman, NewYork, NY, USA, 4th edition, 2000.
12. M. Artac, H. Bozcuk, M. Ozdogan et al., "Different clinical features of primary and secondary tumors in patients with multiple malignancies, " Tumori, vol. 91, no. 4, pp. 317-320, 2005.
13. N. Reymond, B. B. D'água, and A. J. Ridley, "Crossing the endothelial barrier during metastasis, " Nature Reviews Cancer, vol. 13, no. 12, pp. 858-870, 2013.
14. J. E. Rundhaug, "Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor, " Clinical Cancer Research, vol. 9, no. 2, pp. 551-554, 2003.
15. N. Nishida, H. Yano, T. Nishida, T. Kamura, and M. Kojiro, "Angiogenesis in cancer, " Vascular Health and Risk Management, vol. 2, no. 3, pp. 213-219, 2006.
16. C. Blanpain, "Tracing the cellular origin of cancer, " Nature Cell Biology, vol. 15, no. 2, pp. 126-134, 2013.
17. L. H. Sehn, "Introduction to a clinical review series on aggressive B-cell lymphoma, " Blood, vol. 125, no. 1, pp. 1-2, 2015.
18. J. P. Fermand, J. M. James, P. Herait, and J. C. Brouet, "Association chronic lymphocytic leukemia and multiple myeloma: origin from a single clone, " Blood, vol. 66, no. 2, pp. 291-293, 1985.
19. J. Boklan, "Little patients, losing patience: pediatric cancer drug development, " Molecular Cancer Therapeutics, vol. 5, no. 8, pp. 1905-1908, 2006.
20. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
21. K. Murphy, P. Travers, and M. Walport, "Pattern recognition in the innate immune system, " in Janeway's Immunobiology, pp. 39-108, Garland Science/Taylor and Francis Group, New York, NY, USA, 7th edition, 2008.
22. M. Dominguez-Villar, A.-S. Gautron, M. de Marcken, M. J. Keller, and D. A. Hafler, "TLR7 induces anergy in human CD4+ T cells, " Nature Immunology, vol. 16, no. 1, pp. 118-128, 2015.
23. C. A. Dinarello, "Historical review of cytokines, " European Journal of Immunology, vol. 37, supplement 1, pp. S34-S45, 2007.
24. M. Wills-Karp, "Complement activation pathways: a bridge between innate and adaptive immune responses in asthma, " Proceedings of the American Thoracic Society, vol. 4, no. 3, pp. 247-251, 2007.
25. J. C. Sun and L. L. Lanier, "Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity" European Journal of Immunology, vol. 39, no. 8, pp. 2059-2064, 2009.
26. K. Murphy, P. Travers, and M. Walport, "Structural variation in immunoglobulin constant regions, " in Janeway's Immunobiology, pp. 143-213, Garland Science/Taylor and Francis Group, New York, NY, USA, 7th edition, 2008.
27. Y.-H. Chien, R. Jores, and M. P. Crowley, "Recognition by T cells, " Annual Review of Immunology, vol. 14, pp. 511-532, 1996.
28. G. A. Koretzky, "Multiple roles of CD4 and CD8 in T cell activation, " Journal of Immunology, vol. 185, no. 5, pp. 2643-2644, 2010.
29. R. V. Luckheeram, R. Zhou, A. D. Verma, and B. Xia, "CD4 +T cells: differentiation and functions, " Clinical and Developmental Immunology, vol. 2012, Article ID 925135, 12 pages, 2012.
30. J. R. Podojil and S. D. Miller, "Molecular mechanisms of Tcell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy, " Immunological Reviews, vol. 229, no. 1, pp. 337-355, 2009.
31. C. A. Janeway Jr., P. Travers, M. Walport et al., "B-cell activation by armed helper T cells, " in Immunobiology: The Immune System inHealth andDisease, Garland Science, NewYork, NY, USA, 5th edition, 2001.
32. H. W. Schroeder Jr. and L. Cavacini, "Structure and function of immunoglobulins, " Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. S41-S52, 2010.
33. M. Terabe and J. A. Berzofsky, "The role of NKT cells in tumor immunity, " Advances in Cancer Research, vol. 101, pp. 277-348, 2008.
34. D. D. Chaplin, "Overview of the immune response, " Journal of Allergy and Clinical Immunology, vol. 125, no. 2, pp. S3-S23, 2010.
35. J. R. Dunkelberger and W.-C. Song, "Complement and its role in innate and adaptive immune responses, " Cell Research, vol. 20, no. 1, pp. 34-50, 2010.
36. W.-H. Kwan, W. Van Der Touw, and P. S. Heeger, "Complement regulation of T cell immunity, " Immunologic Research, vol. 54, no. 1-3, pp. 247-253, 2012.
37. I. Waldhauer and A. Steinle, "NK cells and cancer immunosurveillance, " Oncogene, vol. 27, no. 45, pp. 5932-5943, 2008.
38. R. Warrington, W. Watson, H. Kim, and F. Antonetti, "An introduction to immunology and immunopathology, " Allergy, Asthma & Clinical Immunology, vol. 7, article S1, 2011.
39. D. S. Chen and I. Mellman, "Oncology meets immunology: the cancer-immunity cycle, " Immunity, vol. 39, no. 1, pp. 1-10, 2013.
40. G. P. Dunn, C. M. Koebel, and R. D. Schreiber, "Interferons, immunity and cancer immunoediting, " Nature Reviews Immunology, vol. 6, no. 11, pp. 836-848, 2006.
41. R. Pio, L. Corrales, and J. D. Lambris, "The role of complement in tumor growth, " Advances in Experimental Medicine and Biology, vol. 772, pp. 229-262, 2014.
42. A. D. Gregory and A. M. Houghton, "Tumor-associated neutrophils: new targets for cancer therapy, " Cancer Research, vol. 71, no. 7, pp. 2411-2416, 2011.
43. K. Palucka and J. Banchereau, "Cancer immunotherapy via dendritic cells, " Nature Reviews Cancer, vol. 12, no. 4, pp. 265-277, 2012.
44. D. Gogoi and S. V. Chiplunkar, "Targeting gamma delta T cells for cancer immunotherapy: bench to bedside, " The Indian Journal of Medical Research, vol. 138, pp. 755-761, 2013.
45. A. H. Sharpe, "Mechanisms of costimulation, " Immunological Reviews, vol. 229, no. 1, pp. 5-11, 2009.
46. T. J. Harris and C. G. Drake, "Primer on tumorimmunology and cancer immunotherapy, " Journal for Immunotherapy of Cancer, vol. 1, article 12, 2013.
47. Y. Minami, T. Kono, T. Miyazaki, and T. Taniguchi, "The IL-2 receptor complex: its structure, function, and target genes, " Annual Review of Immunology, vol. 11, pp. 245-267, 1993.
48. J. Crespo, H. Sun, T. H. Welling, Z. Tian, and W. Zou, "T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment, " Current Opinion in Immunology, vol. 25, no. 2, pp. 214-221, 2013.
49. E. Contardi, G. L. Palmisano, P. L. Tazzari et al., "CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction, " International Journal of Cancer, vol. 117, no. 4, pp. 538-550, 2005.
50. H. Nishikawa and S. Sakaguchi, "Regulatory T cells in tumor immunity, " International Journal of Cancer, vol. 127, no. 4, pp. 759-767, 2010.
51. M. Gobert, I. Treilleux, N. Bendriss-Vermare et al., "Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical utcome, " Cancer Research, vol. 69, no. 5, pp. 2000-2009, 2009.
52. D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, "New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape, " Current Opinion in Immunology, vol. 27, no. 1, pp. 16-25, 2014.
53. G. P. Dunn, L. J. Old, and R. D. Schreiber, "The three Es of cancer immunoediting, " Annual Review of Immunology, vol. 22, pp. 329-360, 2004.
54. I. Mellman, G. Coukos, and G. Dranoff, "Cancer immunotherapy comes of age, " Nature, vol. 480, no. 7378, pp. 480-489, 2011.
55. R. Mandal and T. A. Chan, "Personalized oncology meets immunology: the path toward precision immunotherapy, " Cancer Discovery, vol. 6, no. 7, 2016.
56. J. A. Bluestone and Q. Tang, "Immunotherapy: making the case for precision medicine, " Science Translational Medicine, vol. 7, no. 280, Article ID 280ed3, 2015.
57. M. A. Cheever and C. S. Higano, "PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine, " Clinical Cancer Research, vol. 17, no. 11, pp. 3520-3526, 2011.
58. Y. Shi, C. H. Liu, A. I. Roberts et al., "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know, " Cell Research, vol. 16, no. 2, pp. 126-133, 2006.
59. J. T. Schiller and D. R. Lowy, "Vaccines to prevent infections by oncoviruses, " Annual Review ofMicrobiology, vol. 64, pp. 23-41, 2010.
60. L. M. Weiner, M. V. Dhodapkar, and S. Ferrone, "Monoclonal antibodies for cancer immunotherapy, " The Lancet, vol. 373, no. 9668, pp. 1033-1040, 2009.
61. M. Aris and M. M. Barrio, "Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment, " Frontiers in Immunology, vol. 6, article 46, 2015.
62. C. Krasner and R. M. Joyce, "Zevalin-: 90ytrium labeled anti-CD20 (Ibritumomab tiuxe tan), a new treatment for non-Hodgkin's lymphoma, " Current Pharmaceutical Biotechnology, vol. 2, no. 4, pp. 341-349, 2001.
63. D. Przepiorka, C.-W. Ko, A. Deisseroth et al., "FDA approval: blinatumomab, " Clinical Cancer Research, vol. 21, no. 18, pp. 4035-4039, 2015.
64. K. Wang, G. Wei, and D. Liu, "CD19: a biomarker for B cell development, lymphoma diagnosis and therapy, " Experimental Hematology & Oncology, vol. 1, article 36, 2012.
65. B. H. Nelson, "IL-2, regulatory T cells, and tolerance, " The Journal of Immunology, vol. 172, no. 7, pp. 3983-3988, 2004.
66. J. N. Patel and C. M. Walko, "Sylatron: a pegylated interferon for use in melanoma, " The Annals of Pharmacotherapy, vol. 46, no. 6, pp. 830-838, 2012.
67. P. C. Buchsel, A. Forgey, F. B. Grape, and S. S. Hamann, "Granulocyte macrophage colony-stimulating factor: current practice and novel approaches, " Clinical Journal of Oncology Nursing, vol. 6, no. 4, pp. 198-205, 2002.
68. G. L. Uy, M. P. Rettig, and A. F. Cashen, "Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells, " Expert Opinion on Biological Therapy, vol. 8, no. 11, pp. 1797-1804, 2008.
69. F. Tögel, J. Isaac, Z. Hu, K. Weiss, and C. Westenfelder, "Renal SDF-1 signalsmobilization and homing ofCXCR4-positive cells to the kidney after ischemic injury, " Kidney International, vol. 67, no. 5, pp. 1772-1784, 2005.
70. M. S. Magee and A. Snook, "Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer, " Discovery Medicine, vol. 18, no. 100, pp. 265-271, 2014.
71. S. C. Formenti and S. Demaria, "Systemic effects of local radiotherapy, " The Lancet Oncology, vol. 10, no. 7, pp. 718-726, 2009.
72. R. Duran-Struuck and R. C. Dysko, "Principles of BoneMarrow Transplantation (BMT): providing optimal veterinary and husbandry care to irradiated mice in BMT studies, " Journal of the American Association for Laboratory Animal Science, vol. 48, no. 1, pp. 11-22, 2009.
73. F. Li, C. Zhao, and L. Wang, "Molecular-targeted agents combination therapy for cancer: developments and potentials, " International Journal of Cancer, vol. 134, no. 6, pp. 1257-1269, 2014.
74. C. G. Drake, "Combination immunotherapy approaches, " Annals of Oncology, vol. 23, no. 8, pp. viii41-viii46, 2012.
75. J. D. Wolchok, H. Kluger, M. K. Callahan et al., "Nivolumab plus Ipilimumab in advanced melanoma, "The New England Journal of Medicine, vol. 369, no. 2, pp. 122-133, 2013.
76. L. M. Dong, J. D. Potter, E. White, C. M. Ulrich, L. R. Cardon, and U. Peters, "Genetic susceptibility to cancer: the role of polymorphisms in candidate genes, " Journal of the American Medical Association, vol. 299, no. 20, pp. 2423-2436, 2008.